GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Other Gross PPE

Cambium Bio (ASX:CMB) Other Gross PPE : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Other Gross PPE?

Cambium Bio's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Cambium Bio's annual Other Gross PPE declined from Jun. 2021 (A$0.01 Mil) to Jun. 2022 (A$0.01 Mil) and declined from Jun. 2022 (A$0.01 Mil) to Jun. 2023 (A$0.00 Mil).


Cambium Bio Other Gross PPE Historical Data

The historical data trend for Cambium Bio's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Other Gross PPE Chart

Cambium Bio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 0.01 0.01 -

Cambium Bio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - - -

Cambium Bio Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Cambium Bio (ASX:CMB) Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines